WO1998016186A3 - Monocyclic l-nucleosides, analogs and uses thereof - Google Patents

Monocyclic l-nucleosides, analogs and uses thereof

Info

Publication number
WO1998016186A3
WO1998016186A3 PCT/US1997/018767 US9718767W WO9816186A3 WO 1998016186 A3 WO1998016186 A3 WO 1998016186A3 US 9718767 W US9718767 W US 9718767W WO 9816186 A3 WO9816186 A3 WO 9816186A3
Authority
WO
WIPO (PCT)
Prior art keywords
monocyclic
compounds
useful
nucleosides
analogs
Prior art date
Application number
PCT/US1997/018767
Other languages
French (fr)
Other versions
WO1998016186A2 (en
Inventor
Kandasamy Ramasamy
Robert Tam
Devron Averett
Original Assignee
Icn Pharmaceuticals
Kandasamy Ramasamy
Robert Tam
Devron Averett
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ334915A priority Critical patent/NZ334915A/en
Priority to SK471-99A priority patent/SK284054B6/en
Priority to DK97912762T priority patent/DK1027359T3/en
Priority to PL97333419A priority patent/PL187107B1/en
Priority to EP97912762A priority patent/EP1027359B9/en
Priority to CA002267279A priority patent/CA2267279A1/en
Priority to DE69721339T priority patent/DE69721339T2/en
Priority to UA99042175A priority patent/UA63915C2/en
Priority to AT97912762T priority patent/ATE238328T1/en
Priority to IL12912697A priority patent/IL129126A0/en
Application filed by Icn Pharmaceuticals, Kandasamy Ramasamy, Robert Tam, Devron Averett filed Critical Icn Pharmaceuticals
Priority to AU49867/97A priority patent/AU738170B2/en
Priority to SI9720065A priority patent/SI20076A/en
Priority to JP51861298A priority patent/JP2002503212A/en
Priority to BR9712527-0A priority patent/BR9712527A/en
Priority to HU0001107A priority patent/HUP0001107A3/en
Publication of WO1998016186A2 publication Critical patent/WO1998016186A2/en
Publication of WO1998016186A3 publication Critical patent/WO1998016186A3/en
Priority to NO19991785A priority patent/NO313417B1/en
Priority to US09/633,493 priority patent/US6552183B1/en
Priority to HK00106873A priority patent/HK1028977A1/en
Priority to US09/969,355 priority patent/US6573248B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Abstract

Novel monocyclic L-nucleoside compounds have general formula (I). Embodiments of these compounds are contemplated to be useful in treating a wide variety of diseases including infections, infestations, neoplasms, and autoimmune diseases. Viewed in terms of mechanism, embodiments of the novel compounds show immunomodulatory activity, and are expected to be useful in modulating the cytokine pattern, including modulation of Th1 and Th2 response.
PCT/US1997/018767 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and uses thereof WO1998016186A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
AU49867/97A AU738170B2 (en) 1996-10-16 1997-10-15 Monocyclic L-nucleosides, analogs and uses thereof
SK471-99A SK284054B6 (en) 1996-10-16 1997-10-15 Monocyclic L-nucleosides, analogs and uses thereof
PL97333419A PL187107B1 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, their analoques and application of these compounds
EP97912762A EP1027359B9 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and uses thereof
CA002267279A CA2267279A1 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and uses thereof
DE69721339T DE69721339T2 (en) 1996-10-16 1997-10-15 MONOCYCLIC L-NUCLEOSIDES, ANALOGS AND THEIR APPLICATIONS
UA99042175A UA63915C2 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogues and use thereof
SI9720065A SI20076A (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and use thereof
IL12912697A IL129126A0 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides analogs and uses thereof
NZ334915A NZ334915A (en) 1996-10-16 1997-10-15 Monocyclic L-nucleosides, analogs thereof and their use in the modulation of Th1 and Th2 activities
DK97912762T DK1027359T3 (en) 1996-10-16 1997-10-15 Monocyclic L-nucleosides, analogs and uses thereof
AT97912762T ATE238328T1 (en) 1996-10-16 1997-10-15 MONOCYCLIC L-NUCLEOSIDES, ANALOGAS AND THEIR APPLICATIONS
JP51861298A JP2002503212A (en) 1996-10-16 1997-10-15 Monocyclic nucleosides, analogs and uses thereof
BR9712527-0A BR9712527A (en) 1996-10-16 1997-10-15 Monocyclic L-nucleosides, analogues and their uses
HU0001107A HUP0001107A3 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and pharmaceutical compositions thereof
NO19991785A NO313417B1 (en) 1996-10-16 1999-04-15 Monocyclic L-nucleosides, analogs and uses thereof
US09/633,493 US6552183B1 (en) 1996-10-16 2000-08-07 Moncyclic L-nucleosides analogs
HK00106873A HK1028977A1 (en) 1996-10-16 2000-10-28 Monocyclic l-nucleosides, analogs and uses thereof
US09/969,355 US6573248B2 (en) 1996-10-16 2001-12-31 Monocyclic L-nucleosides, analogs and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2858596P 1996-10-16 1996-10-16
US60/028,585 1996-10-16

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/291,903 Continuation US6130326A (en) 1996-10-16 1999-04-14 Monocyclic L-Nucleosides, analogs and uses thereof
US09/291,903 A-371-Of-International US6130326A (en) 1996-10-16 1999-04-14 Monocyclic L-Nucleosides, analogs and uses thereof
US09/633,493 Division US6552183B1 (en) 1996-10-16 2000-08-07 Moncyclic L-nucleosides analogs
US09/633,493 Continuation US6552183B1 (en) 1996-10-16 2000-08-07 Moncyclic L-nucleosides analogs

Publications (2)

Publication Number Publication Date
WO1998016186A2 WO1998016186A2 (en) 1998-04-23
WO1998016186A3 true WO1998016186A3 (en) 1998-06-11

Family

ID=21844262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018767 WO1998016186A2 (en) 1996-10-16 1997-10-15 Monocyclic l-nucleosides, analogs and uses thereof

Country Status (26)

Country Link
US (4) US6130326A (en)
EP (1) EP1027359B9 (en)
JP (2) JP2002503212A (en)
KR (1) KR100398923B1 (en)
CN (1) CN1268140A (en)
AT (2) ATE236921T1 (en)
AU (1) AU738170B2 (en)
BR (1) BR9712527A (en)
CA (1) CA2267279A1 (en)
CZ (1) CZ120699A3 (en)
DE (2) DE69721339T2 (en)
DK (2) DK1027359T3 (en)
ES (2) ES2195970T3 (en)
HK (2) HK1038365A1 (en)
HU (1) HUP0001107A3 (en)
IL (1) IL129126A0 (en)
NO (1) NO313417B1 (en)
NZ (1) NZ334915A (en)
PL (1) PL187107B1 (en)
PT (2) PT1027359E (en)
RU (2) RU2188828C2 (en)
SI (1) SI20076A (en)
SK (1) SK284054B6 (en)
UA (1) UA63915C2 (en)
WO (1) WO1998016186A2 (en)
YU (1) YU18799A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK284054B6 (en) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
YU67099A (en) * 1997-06-30 2002-06-19 Icn Pharmaceuticals Inc. Method for producing tiazofurin and other c-nucleosides
JP4596495B2 (en) * 1997-07-18 2010-12-08 ソニー株式会社 CONTROL DEVICE, CONTROL METHOD, ELECTRIC DEVICE SYSTEM, ELECTRIC DEVICE SYSTEM CONTROL METHOD, AND RECORDING MEDIUM
US7901400B2 (en) 1998-10-23 2011-03-08 Covidien Ag Method and system for controlling output of RF medical generator
KR100618028B1 (en) 1998-11-05 2006-08-30 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 Nucleosides with anti-hepatitis B virus activity
MXPA01004505A (en) * 1998-11-05 2005-04-19 Centre Nat Rech Scient beta-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HIV INFECTION.
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
HUP0200027A2 (en) * 1999-01-29 2002-04-29 Icn Pharmaceuticals Modulation of immune response by ribavirin
US7084125B2 (en) 1999-03-18 2006-08-01 Exiqon A/S Xylo-LNA analogues
ATE356824T1 (en) 1999-05-04 2007-04-15 Santaris Pharma As L-RIBO-LNA ANALOGUE
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
EP1208109A2 (en) * 1999-08-31 2002-05-29 Nycomed Amersham Plc Nucleoside analogues
US6664399B1 (en) * 1999-09-02 2003-12-16 E. I. Du Pont De Nemours & Company Triazole linked carbohydrates
US6518253B1 (en) * 1999-11-19 2003-02-11 Robert Tam Treatment of viral infections using the L-isomer of ribavirin
CZ20022112A3 (en) * 1999-12-23 2003-05-14 Ribapharm Inc. Preparations and methods relating to L-nucleosides, L-nucleotides, and their analog
US6495677B1 (en) 2000-02-15 2002-12-17 Kanda S. Ramasamy Nucleoside compounds
US6455508B1 (en) * 2000-02-15 2002-09-24 Kanda S. Ramasamy Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
BR0110023A (en) * 2000-04-13 2003-12-30 Pharmasset Ltd Substituted 3'-or-2 'nucleoside derivatives for treatment of hepatitis virus infections
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
KR20080021797A (en) * 2000-05-26 2008-03-07 이데닉스(케이만)리미티드 Methods and compositions for treating flaviviruses and pestiviruses
US6815542B2 (en) * 2000-06-16 2004-11-09 Ribapharm, Inc. Nucleoside compounds and uses thereof
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6680059B2 (en) * 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002014362A2 (en) 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US6720000B2 (en) * 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
DE60101056T2 (en) * 2001-07-30 2004-05-19 Clariant Life Science Molecules (Italia) S.P.A., Origgio Process for the preparation of ribavirin
AU2002330154A1 (en) * 2001-09-28 2003-04-07 Centre National De La Recherche Scientifique Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
IL161697A0 (en) * 2001-11-02 2004-09-27 Sandoz Ag Process for preparing quick dissolving, high loading ribavirin compositions
KR100411398B1 (en) * 2001-12-06 2003-12-18 주식회사유한양행 A PROCESS FOR THE PREPARATION OF β-D-RIBOFURANOSE DERIVATIVES
WO2003073989A2 (en) * 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
WO2003092520A1 (en) 2002-05-06 2003-11-13 Sherwood Services Ag Blood detector for controlling anesu and method therefor
US6982253B2 (en) 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
CA2489552A1 (en) 2002-06-28 2004-01-08 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN101172993A (en) * 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0313164A (en) * 2002-08-01 2007-07-17 Pharmasset Inc compounds with the non-bicyclic system [4.2.1] for the treatment of flaviviridae infections
AU2003253380A1 (en) * 2002-08-12 2004-03-11 F. Hoffmann-La-Roche Ag Process for producing a ribofuranose
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
US20040077607A1 (en) * 2002-10-21 2004-04-22 Uckun Fatih M. Aryl phosphate derivatives of d4T with potent anti-viral activity against hemorrhagic fever viruses
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
MXPA05005192A (en) * 2002-11-15 2005-09-08 Idenix Cayman Ltd 2aCOE-BRANCHED NUCLEOSIDES AND FLAVIVIRIDAE.
US7044948B2 (en) 2002-12-10 2006-05-16 Sherwood Services Ag Circuit for controlling arc energy from an electrosurgical generator
WO2004052899A2 (en) * 2002-12-12 2004-06-24 Idenix (Cayman) Limited Process for the production of 2'-branched nucleosides
KR20050110611A (en) * 2002-12-23 2005-11-23 이데닉스 (케이만) 리미티드 Process for the production of 3'-nucleoside prodrugs
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) * 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
BRPI0408846A (en) * 2003-03-28 2006-07-04 Pharmasset Inc compounds for the treatment of flaviviridae infections
EP1617776B1 (en) 2003-05-01 2015-09-02 Covidien AG System for programing and controlling an electrosurgical generator system
SI3521297T1 (en) 2003-05-30 2022-04-29 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
US20050009848A1 (en) * 2003-07-10 2005-01-13 Icn Pharmaceuticals Switzerland Ltd. Use of antivirals against inflammatory bowel diseases
DE602004028841D1 (en) * 2003-07-25 2010-10-07 Centre Nat Rech Scient PURIN NUCLEOSIDE FOR THE TREATMENT OF FLAVIVIDRAIC DISEASES, INCLUDING HEPATITIS C
WO2005018330A1 (en) * 2003-08-18 2005-03-03 Pharmasset, Inc. Dosing regimen for flaviviridae therapy
AU2003284929B2 (en) 2003-10-23 2010-07-22 Covidien Ag Redundant temperature monitoring in electrosurgical systems for safety mitigation
AU2003286644B2 (en) 2003-10-23 2009-09-10 Covidien Ag Thermocouple measurement circuit
US7396336B2 (en) 2003-10-30 2008-07-08 Sherwood Services Ag Switched resonant ultrasonic power amplifier system
US7131860B2 (en) 2003-11-20 2006-11-07 Sherwood Services Ag Connector systems for electrosurgical generator
US7766905B2 (en) 2004-02-12 2010-08-03 Covidien Ag Method and system for continuity testing of medical electrodes
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
US7780662B2 (en) 2004-03-02 2010-08-24 Covidien Ag Vessel sealing system using capacitive RF dielectric heating
WO2006000922A2 (en) * 2004-06-23 2006-01-05 Idenix (Cayman) Limited 5-aza-7-deazapurine derivatives for treating infections with flaviviridae
CN101023094B (en) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
ES2725457T3 (en) 2004-09-14 2019-09-24 Gilead Pharmasset Llc Preparation of ribofuranosyl pyrimidines and 2'fluoro-2'-alkyl-substituted or other optionally substituted purines and their derivatives
WO2006074416A1 (en) * 2005-01-07 2006-07-13 Health Research Inc. 5-amino-4-imidazolecarboxamide riboside and its nucleobase as potentiators of antifolate transport and metabolism
US7250416B2 (en) 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
JP4516863B2 (en) * 2005-03-11 2010-08-04 株式会社ケンウッド Speech synthesis apparatus, speech synthesis method and program
EP1877054A2 (en) * 2005-03-30 2008-01-16 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
EP1888751A2 (en) * 2005-05-25 2008-02-20 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US8734438B2 (en) 2005-10-21 2014-05-27 Covidien Ag Circuit and method for reducing stored energy in an electrosurgical generator
US7947039B2 (en) 2005-12-12 2011-05-24 Covidien Ag Laparoscopic apparatus for performing electrosurgical procedures
WO2007075876A2 (en) 2005-12-23 2007-07-05 Idenix Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US7651493B2 (en) 2006-03-03 2010-01-26 Covidien Ag System and method for controlling electrosurgical snares
BRPI0708363A2 (en) * 2006-03-09 2011-05-24 Om Pharma process for the treatment of warm-blooded animals, including humans, suffering from a disease related to inflammatory cytokine overproduction
FR2907786B1 (en) * 2006-10-27 2009-09-18 Univ Grenoble 1 THIONUCLEOSIDES AND PHARMACEUTICAL APPLICATIONS
AU2007325551A1 (en) * 2006-09-11 2008-06-05 Arrowhead Center Inc. Azole nucleosides and use as inhibitors of RNA and DNA varial polymerases
WO2008069303A1 (en) * 2006-12-08 2008-06-12 Api Corporation Method for production of furanose derivative
WO2008086341A1 (en) * 2007-01-09 2008-07-17 Pericor Therapeutics, Inc. Methods. compositions, and formulations for preventing or reducing adverse effects in a patient
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
ES2824261T3 (en) 2007-09-14 2021-05-11 Biogen Ma Inc Compositions and procedures for the treatment of progressive multifocal leukoencephalopathy (PML)
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
WO2009130588A2 (en) * 2008-04-22 2009-10-29 Tripep Ab Immunogen platform
DK2695609T3 (en) 2008-05-15 2020-02-10 Celgene Corp Oral formulations of cytidine analogues and methods for their use
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2748057C (en) 2008-12-23 2018-07-03 Pharmasset, Inc. Nucleoside phosphoramidates
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TW201031675A (en) 2008-12-23 2010-09-01 Pharmasset Inc Synthesis of purine nucleosides
CN102421293A (en) * 2009-03-20 2012-04-18 艾丽奥斯生物制药有限公司 Substituted nucleoside and nucleotide analogs
TWI583692B (en) * 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
KR101715981B1 (en) 2010-03-31 2017-03-13 길리애드 파마셋 엘엘씨 Nucleoside phosphoramidates
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
KR20130110170A (en) 2010-09-22 2013-10-08 앨리오스 바이오파마 인크. Substituted nucleotide analogs
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
EP3042910B1 (en) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucleosides for use in the therapy of hepatitis c
GB201021867D0 (en) * 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
CN102153548B (en) * 2011-02-24 2012-11-28 河北大学 Analogue nucleoside derivative containing thiazolidone (thiazinidone) ring, preparation method and application thereof to medicinal preparations
CN103619864A (en) 2011-03-31 2014-03-05 细胞基因国际有限公司 Systhesis of 5-azacytidine
BR112014004779B1 (en) 2011-08-30 2022-01-18 Astex Pharmaceuticals, Inc DECITABINE DERIVATIVES FORMULATIONS, KIT AND RELATED PROCESSES
DE202012013382U1 (en) 2011-09-16 2016-08-23 Gilead Pharmasset Llc Compositions for the treatment of HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
AU2012358804B2 (en) 2011-12-22 2018-04-19 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
DK2794627T3 (en) 2011-12-22 2019-01-14 Alios Biopharma Inc SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGUES THEREOF
CN104321333A (en) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 Solid forms of a thiophosphoramidate nucleotide prodrug
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
MX2014014323A (en) 2012-05-25 2015-02-12 Janssen R & D Ireland Uracyl spirooxetane nucleosides.
ES2865402T3 (en) 2012-12-21 2021-10-15 Janssen Biopharma Inc 4'-fluoronucleosides, 4'-fluoronucleotides and analogues thereof for the treatment of HCV
PT2950786T (en) 2013-01-31 2020-03-03 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
ES2623287T3 (en) 2013-04-12 2017-07-10 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for HCV treatment
SI3650014T1 (en) 2013-08-27 2022-01-31 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2015205342B2 (en) 2014-01-07 2020-01-23 Babita Agrawal Immunomodulatory compositions and methods of use thereof
JP2017512183A (en) 2014-02-13 2017-05-18 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
US10485814B2 (en) 2014-06-06 2019-11-26 Glaxosmithkline Intellectual Property (No. 2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
JP2017520545A (en) 2014-07-02 2017-07-27 リガンド・ファーマシューティカルズ・インコーポレイテッド Prodrug compounds and their use
AU2016239844B2 (en) 2015-04-02 2021-05-13 Ablynx N.V. Bispecific CXCR4-CD-4 polypeptides with potent anti-HIV activity
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
WO2017218580A1 (en) 2016-06-14 2017-12-21 Rejuvenation Therapeutics Corporation Synthetic methods for the preparation of nicotinamide riboside and related compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
RU2624018C2 (en) * 2016-09-26 2017-06-30 Федеральное государственное бюджетное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН (ИБХ РАН) 5-(tetrahydrofuran-2-yl)-1,2,4-triazole-3-carboxylic acid amide with antiviral activity, and method for production
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
WO2020157694A1 (en) * 2019-02-01 2020-08-06 Janssen Biopharma, Inc. Antiviral nucleosides and derivatives thereof
UY38979A (en) 2019-12-06 2021-07-30 Vertex Pharma TETRAHYDROFURANS REPLACED AS SODIUM CHANNEL MODULATORS
AR126073A1 (en) 2021-06-04 2023-09-06 Vertex Pharma N-(HYDROXYALKYL(HETERO)ARYL)TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS
WO2023288047A2 (en) * 2021-07-15 2023-01-19 Alnylam Pharmaceuticals, Inc. Multiplexing targeting ligands through click chemistry at the anomeric site of sugars

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948885A (en) * 1973-03-19 1976-04-06 Icn Pharmaceuticals, Inc. 5-Hydroxyl-1,2,3-triazole-4-carboxamide nucleoside
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
US4992426A (en) * 1989-02-27 1991-02-12 Nucleic Acid Research Institute Antiparasitic 5'-sulfamoyl nucleosides
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5561120A (en) * 1993-05-25 1996-10-01 Yale University Method for treating HBV infections with L-2',3'-didehydro-dideoxy-5-fluorocytidine
US5565438A (en) * 1994-01-28 1996-10-15 University Of Ga Research Foundation L-nucleosides for the treatment of epstein-bar virus
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides
US5681947A (en) * 1992-09-16 1997-10-28 Purdue Research Foundation Oligonucleotides having universal nucleoside spacers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0054432B1 (en) * 1980-12-15 1990-01-31 Viratek, Inc. Use of 2-beta-d-ribofuranosylthiazole-4-carboxamides for the manufacture of medicaments inhibiting malignant tumors
JPS60193997A (en) * 1984-03-14 1985-10-02 Sumitomo Chem Co Ltd New cyanoimidazole ribonucleoside derivative and its preparation
CA1317588C (en) * 1988-02-29 1993-05-11 Tohru Ueda Imidazole derivatives, process for production thereof, and use thereof
IT1246983B (en) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-DESOXYURIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
WO1994021658A1 (en) * 1993-03-15 1994-09-29 Kalman Thomas I Antiviral imidazolinone nucleoside derivatives
DE19518216A1 (en) * 1994-10-07 1996-04-11 Max Delbrueck Centrum New β-L nucleosides and their use
IT1281498B1 (en) * 1995-06-07 1998-02-18 Sardinian Antiviral Research C PYRAZOLE - DERIVATIVES WITH ANTI-CANCER ACTIVITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, AND
SK284054B6 (en) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948885A (en) * 1973-03-19 1976-04-06 Icn Pharmaceuticals, Inc. 5-Hydroxyl-1,2,3-triazole-4-carboxamide nucleoside
US4138547A (en) * 1977-12-22 1979-02-06 Icn Pharmaceuticals, Inc. Process for preparing 1,2,4-triazole nucleosides
US5082829A (en) * 1989-01-24 1992-01-21 Gensia Pharmaceuticals AICA riboside prodrugs
US4992426A (en) * 1989-02-27 1991-02-12 Nucleic Acid Research Institute Antiparasitic 5'-sulfamoyl nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5681947A (en) * 1992-09-16 1997-10-28 Purdue Research Foundation Oligonucleotides having universal nucleoside spacers
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
US5561120A (en) * 1993-05-25 1996-10-01 Yale University Method for treating HBV infections with L-2',3'-didehydro-dideoxy-5-fluorocytidine
US5631239A (en) * 1993-05-25 1997-05-20 Yale University L-2',3'-dideoxy nucleoside analogs as anti-Hepatitis B (HBV) agents
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US5565438A (en) * 1994-01-28 1996-10-15 University Of Ga Research Foundation L-nucleosides for the treatment of epstein-bar virus
US5567688A (en) * 1994-01-28 1996-10-22 Univ. Of Ga Research Foundation L-nucleosides for the treatment of hepatitis B-virus
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN DRAANEN ET AL.: "Influence of Stereochemistry on Antiviral Activities and Resistance Profiles of Dideoxycytidine Nucleosides", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 38, no. 4, April 1994 (1994-04-01), pages 868 - 871, XP002947715 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883169B2 (en) 2007-08-16 2014-11-11 Chrontech Pharma Ab Immunogen platform
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Also Published As

Publication number Publication date
HK1038365A1 (en) 2002-03-15
US6130326A (en) 2000-10-10
US6552183B1 (en) 2003-04-22
ATE236921T1 (en) 2003-04-15
HUP0001107A3 (en) 2003-01-28
HK1028977A1 (en) 2001-03-16
NZ334915A (en) 2000-11-24
SK47199A3 (en) 2000-12-11
CA2267279A1 (en) 1998-04-23
DE69720811T2 (en) 2004-03-11
NO313417B1 (en) 2002-09-30
WO1998016186A2 (en) 1998-04-23
KR20000049224A (en) 2000-07-25
NO991785D0 (en) 1999-04-15
SK284054B6 (en) 2004-08-03
NO991785L (en) 1999-06-15
AU4986797A (en) 1998-05-11
PT1027359E (en) 2003-09-30
HUP0001107A2 (en) 2001-06-28
CZ120699A3 (en) 1999-09-15
RU2001132536A (en) 2003-08-20
PL187107B1 (en) 2004-05-31
US20020095033A1 (en) 2002-07-18
DK1027359T3 (en) 2003-08-11
US6642206B2 (en) 2003-11-04
JP2002503212A (en) 2002-01-29
DE69720811D1 (en) 2003-05-15
EP1027359A2 (en) 2000-08-16
YU18799A (en) 2002-06-19
PT1132393E (en) 2003-08-29
US6573248B2 (en) 2003-06-03
CN1268140A (en) 2000-09-27
UA63915C2 (en) 2004-02-16
PL333419A1 (en) 1999-12-06
SI20076A (en) 2000-04-30
IL129126A0 (en) 2000-02-17
ATE238328T1 (en) 2003-05-15
RU2188828C2 (en) 2002-09-10
US20030018186A1 (en) 2003-01-23
ES2195970T3 (en) 2003-12-16
EP1027359A4 (en) 2001-07-25
ES2195125T3 (en) 2003-12-01
EP1027359B9 (en) 2003-09-17
DE69721339D1 (en) 2003-05-28
DE69721339T2 (en) 2004-01-22
EP1027359B1 (en) 2003-04-23
AU738170B2 (en) 2001-09-13
KR100398923B1 (en) 2003-09-19
DK1132393T3 (en) 2003-07-21
BR9712527A (en) 2000-03-08
JP2003176296A (en) 2003-06-24

Similar Documents

Publication Publication Date Title
WO1998016186A3 (en) Monocyclic l-nucleosides, analogs and uses thereof
DE289366T1 (en) MEDIUM CONSISTING OF AN ORGANIC COMPOSITION OF THE SILICONE, COMBINED WITH A COSMETICALLY ACTIVE SUBSTANCE.
ATE81505T1 (en) AZACYCLOALKANDERIVATES, ABSORPTION PROMOTERS CONTAINING THE DERIVATIVES AS EFFECTIVE INGREDIENTS AND TOPICAL PREPARATIONS CONTAINING ABSORPTION PROMOTERS.
IT8721271A0 (en) LARGE BALER.
IT8567279A1 (en) EQUIPMENT FOR THE CONTROLLED APPLICATION, ON HUMAN TISSUE, OF REDUCING SUBSTANCES TO REALIZE MICROABRASIONS.
DE68913739D1 (en) COSMETIC AND SKIN TREATMENT COMPOSITIONS.
AU581574B2 (en) Fabric treatment to improve dyeability thereof
MY117323A (en) Method of scavenging free radicals using orange extract
ATE197395T1 (en) EXTERNAL SKIN TREATMENT
AU3419489A (en) Bedding, in particular for persons unable to move
AU4630599A (en) Perfume composition
AU2026900A (en) Neuron stimulation by ribavirin, and analogs thereof
DE69208681T2 (en) USES OF 1,1,1,3,3,3-HEXAFLUOROPROPANE
IL86970A0 (en) Ascorbic acid derivative,its preparation and its use as antioxidant
KR910000144A (en) Pigmentation cure
EP0586154A3 (en) Melanin formation-inhibitory protein, and its preparation and uses.
IT9019303A1 (en) ANTIBIOTIC COMPOUND, JANTINOMYCIN AND PROCEDURE TO PREPARE IT
DE3787371D1 (en) BIOLOGICALLY ACTIVE AGENT.
Johansson Application of Dirac phenomenology to proton inelastic scattering
IT218809Z2 (en) . ANATOMICAL ORTHOPEDIC PANEL TO REST, SLEEP AND CARE
RU95121623A (en) OINTMENT
FI873923A0 (en) REALIZATION MEASURES PAIN BITNIVAO FOER EN SYNTESPROCEDUR VID KRETSPLANERING.
MX9709982A (en) Chalcone retinoids and methods of use of same.
RU96111534A (en) FOOD BIOLOGICALLY ACTIVE ADDITION OF TINROSTIM-S
BR6801156U (en) BEACH TABLE, LAGO, POND, RIO

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180619.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 334915

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2267279

Country of ref document: CA

Ref document number: 2267279

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV1999-1206

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 47199

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003434

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1997912762

Country of ref document: EP

Ref document number: 1019997003326

Country of ref document: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1999-1206

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997003326

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1997912762

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997912762

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019997003326

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV1999-1206

Country of ref document: CZ